Kahimmune is a next generation biotech company pioneering the re exploration of the cancer immunopeptidome to develop synergistic, mRNA-based companion neoantigen therapies (CNT). By deeply mining the “dark genome” through its innovative proprietary platform, Kahinomics™, Kahimmune uncovers novel neoantigens designed to power innovative combination strategies in oncology.